专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010131032A2 NOVEL POLYMERS 审中-公开
标题翻译：新型聚合物
公开(公告)号：WO2010131032A2
公开(公告)日：2010-11-18
申请号：PCT/GB2010/050769
申请日：2010-05-11
申请人： PHARMAPATENTS GLOBAL LTD , MCCORMACK, Keith
发明人： MCCORMACK, Keith
IPC分类号： A61K47/48
CPC分类号： A61K31/795 , A61K47/55 , A61K47/59 , C08G75/00 , C08G75/04
摘要： The present invention relates to polymers comprising monomer units derived from captopril, and their use in the treatment or prevention of collagen deposition, fibrosis, scars, burns, or unwanted tissue formation. The present invention further relates to processes for the preparation of said polymers and to pharmaceutical compositions and medical products comprising the polymers. Also encompassed by the present invention are polymers comprising monomer units derived from other ACE inhibitors such as zofenopril, alacepril, rentiapril or pivalopril, or from vasopeptidase inhibitors such as fasidotrilat, omapatrilat or ilepatril.
摘要翻译：本发明涉及包含衍生自卡托普利的单体单元的聚合物及其在治疗或预防胶原沉积，纤维化，瘢痕，烧伤或不想要的组织形成中的用途。本发明还涉及制备所述聚合物的方法以及包含聚合物的药物组合物和医药产品。本发明还包括包含衍生自其他ACE抑制剂如佐芬普利，阿拉普利，利莫普利或新戊酰胺的单体单元，或来自血管肽酶抑制剂如法西多瑞拉，奥沙曲坦或依他帕替的聚合物。

2. 发明申请

WO0135942A9 ANALGESIC COMPOSITIONS CONTAINING BUPRENORPHINE 审中-公开
标题翻译：含有苯丙胺的组合物
公开(公告)号：WO0135942A9
公开(公告)日：2002-11-28
申请号：PCT/GB0004372
申请日：2000-11-17
申请人： RECKITT BENCKISER HEALTHCARE , CHAPLEO CHRISTOPHER BOURNE , MCCORMACK KEITH , VAREY NICOLAS CALVERT
发明人： CHAPLEO CHRISTOPHER BOURNE , MCCORMACK KEITH , VAREY NICOLAS CALVERT
IPC分类号： A61K9/02 , A61K9/00 , A61K9/08 , A61K9/20 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , A61P25/04
CPC分类号： A61K9/0019 , A61K9/0056 , A61K9/006 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , Y10S514/811 , Y10S514/812 , A61K2300/00
摘要： An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1, whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
摘要翻译：以肠胃外单位剂量形式或以适合于通过粘膜递送的单位剂量形式的镇痛组合物，其包含少于实现疼痛缓解所需的临床剂量的丁丙诺啡和一定量的纳洛酮，使得丁丙诺啡的重量比纳洛酮的量范围为12.5:1至27.5:1，或纳曲酮或纳美芬的量，使得丁丙诺啡与纳曲酮或纳美芬的重量比在12.5:1至22.5:1的范围内，由此丁丙诺啡的镇痛作用被纳洛酮，纳曲酮或纳美芬的低剂量加强。

3. 发明申请

WO2001035942A3 ANALGESIC COMPOSITIONS CONTAINING BUPRENORPHINE 审中-公开
公开(公告)号：WO2001035942A3
公开(公告)日：2001-05-25
申请号：PCT/GB2000/004372
申请日：2000-11-17
申请人： RECKITT BENCKISER HEALTHCARE (UK) LIMITED , CHAPLEO, Christopher, Bourne , MCCORMACK, Keith , VAREY, Nicolas, Calvert
发明人： CHAPLEO, Christopher, Bourne , MCCORMACK, Keith , VAREY, Nicolas, Calvert
IPC分类号： A61K31/485
摘要： An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1, whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.

4. 发明申请

WO2010131032A3 NOVEL POLYMERS 审中-公开
标题翻译：新型聚合物
公开(公告)号：WO2010131032A3
公开(公告)日：2010-12-29
申请号：PCT/GB2010050769
申请日：2010-05-11
申请人： PHARMAPATENTS GLOBAL LTD , MCCORMACK KEITH
发明人： MCCORMACK KEITH
IPC分类号： A61K47/48 , A61K31/795 , C08G75/26
CPC分类号： A61K31/795 , A61K47/55 , A61K47/59 , C08G75/00 , C08G75/04
摘要： The present invention relates to polymers comprising monomer units derived from captopril, and their use in the treatment or prevention of collagen deposition, fibrosis, scars, burns, or unwanted tissue formation. The present invention further relates to processes for the preparation of said polymers and to pharmaceutical compositions and medical products comprising the polymers. Also encompassed by the present invention are polymers comprising monomer units derived from other ACE inhibitors such as zofenopril, alacepril, rentiapril or pivalopril, or from vasopeptidase inhibitors such as fasidotrilat, omapatrilat or ilepatril.
摘要翻译：本发明涉及包含衍生自卡托普利的单体单元的聚合物，以及它们在治疗或预防胶原沉积，纤维化，瘢痕，烧伤或不需要的组织形成中的用途。本发明进一步涉及制备所述聚合物的方法以及包含该聚合物的药物组合物和医药产品。本发明还涵盖包含衍生自其他ACE抑制剂例如佐芬普利，阿拉普利，伦达普利或匹伐普利，或来自血管肽酶抑制剂例如法西多曲，奥马帕曲拉或ilepatril的单体单元的聚合物。

5. 发明申请

WO0135942A2 PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：药物组合物
公开(公告)号：WO0135942A2
公开(公告)日：2001-05-25
申请号：PCT/GB0004372
申请日：2000-11-17
申请人： RECKITT & COLMANN PROD LTD , CHAPLEO CHRISTOPHER BOURNE , MCCORMACK KEITH , VAREY NICOLAS CALVERT
发明人： CHAPLEO CHRISTOPHER BOURNE , MCCORMACK KEITH , VAREY NICOLAS CALVERT
IPC分类号： A61K9/02 , A61K9/00 , A61K9/08 , A61K9/20 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , A61P25/04 , A61K31/00
CPC分类号： A61K9/0019 , A61K9/0056 , A61K9/006 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , Y10S514/811 , Y10S514/812 , A61K2300/00
摘要： An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1, whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
摘要翻译：以胃肠外单位剂量形式或适合于通过粘膜递送的单位剂量形式的止痛组合物，其包含少于实现疼痛缓解所需的临床剂量的丁丙诺啡和一定量的纳洛酮，使得丁丙诺啡的重量比纳洛酮的范围为12.5:1至27.5:1或纳曲酮或纳美芬的量，使得丁丙诺啡与纳曲酮或纳美芬的重量比在12.5:1至22.5:1的范围内，由此丁丙诺啡的镇痛作用被纳洛酮，纳曲酮或纳美芬的低剂量加强。

6. 发明申请

WO9911778B1 ANTISENSE TREATMENT OF PULMONARY HYPERTENSION 审中-公开
标题翻译：反射治疗肺高血压
公开(公告)号：WO9911778B1
公开(公告)日：1999-04-15
申请号：PCT/GB9802584
申请日：1998-09-02
申请人： UNIV SHEFFIELD , HIGENBOTTAM TIMOTHY , MCCORMACK KEITH , SMITH ADRIAN
发明人： HIGENBOTTAM TIMOTHY , MCCORMACK KEITH , SMITH ADRIAN
IPC分类号： C12N15/09 , A61K31/708 , A61K38/00 , A61M11/00 , A61M15/00 , A61P3/06 , C12N15/113 , C12N15/11 , A61K31/70
CPC分类号： C12N15/1136 , A61K38/00
摘要： The invention herein described relates to a method to treat pulmonary hypertension by antisense therapy using ET-1 derived antisense molecules delivered to the lungs as a pulse/spike in an inhaler.
摘要翻译：在此描述的本发明涉及一种通过使用ET-1衍生的反义分子通过反义疗法治疗肺高血压的方法，所述反义分子作为吸入器中的脉冲/刺突递送至肺。

7. 发明申请

WO2010035047A1 BINARY COMPOSITIONS COMPRISING AN NO-DONOR AND AN A-SMASE INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES 审中-公开
标题翻译：包含免疫抑制剂和用于治疗呼吸道疾病的A-SMASE抑制剂的二元组合物
公开(公告)号：WO2010035047A1
公开(公告)日：2010-04-01
申请号：PCT/GB2009/051262
申请日：2009-09-25
申请人： PHARMAPATENTS GLOBAL LTD. , MCCORMACK, Keith
发明人： MCCORMACK, Keith
IPC分类号： A61K31/55 , A61K31/198
CPC分类号： A61K31/198 , A61K31/55 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising an A-SMase inhibitor and/or a NO-donor. Preferred A-SMase inhibitors are tricyclic antidepressants, most preferably amitriptyline. A preferred NO-donor is arginine. Preferably the pharmaceutical composition comprises an A-SMase inhibitor and a NO-donor, which preferably act synergistically to inhibit A-SMase. The pharmaceutical composition is suitable for treating or preventing respiratory disorders such as chronic cough, cystic fibrosis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and emphysema. Preferably the pharmaceutical composition is administered by inhalation. The present invention also relates to methods of treating or preventing respiratory disorders, methods of inhibiting A-SMase, and assays for investigating the effect of test compounds upon A-SMase activity in vitro.
摘要翻译：本发明涉及包含A-SMase抑制剂和/或NO供体的药物组合物。优选的A-SMase抑制剂是三环抗抑郁药，最优选阿米替林。优选的NO供体是精氨酸。优选地，药物组合物包含A-SMase抑制剂和NO供体，其优选协同作用以抑制A-SMase。该药物组合物适用于治疗或预防呼吸系统疾病，如慢性咳嗽，囊性纤维化，慢性阻塞性肺病，特发性肺纤维化和肺气肿。优选地，药物组合物通过吸入给药。本发明还涉及治疗或预防呼吸系统疾病的方法，抑制A-SMase的方法，以及用于研究试验化合物对体外A-SMase活性的影响的测定方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式